



ADVANCED PROSTATE CANCER CONSENSUS CONFERENCE

St.Gallen / Switzerland 12 – 14 March 2015

Advanced Prostate Cancer Consensus Conference (APCCC)

St.Gallen / Switzerland

SAVE THE DATE: 12 -14 March 2015



www.prostatecancerconsensus.org

The **Advanced Prostate Cancer Consensus Conference APCCC** will:

- Provide an update on the current **standard of advanced prostate cancer** management.
- Program will be **highly educational**, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary **prostate cancer experts**.
- The conference will culminate on Saturday with an **interdisciplinary expert consensus panel meeting** that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. **Participants will be able to attend** the panel meeting as part of the conference.
- The **consensus summary** will be submitted for publication after the meeting in a high impact medical journal.
- Attendees will be able to **interact with panel members**, facilitating and encouraging international collaboration.

Consensus Expert Panel

Attard G, UK
Beltran H, US
Chi K, Canada
Chinnaiyan A, US
Daugaard G, Denmark
Davis I, Australia
De Bono J, UK
De Santis M, Austria
Drake C, US
Eeles R, UK
Efsthathiou E, Greece/US
Fanti S, Italy
Fizazi K, France
Gillesen S, Switzerland

Gleave M, Canada
Halabi S, US
Heidenreich A, Germany
Hussain M, US
James N, UK
Lecouvet B, Belgium
Logothetis C, US
Nelson P, US
Nilsson S, Sweden
Oh W, US
Olmos D, Spain
Padhani A, UK
Parker C, UK
Rubin M, US

Ryan C, US
Sartor O, US
Schalken J, Holland
Scher H, US
Sella A, Israel
Shore N, US
Small E, US
Smith M, US
Soule H, US (Scientific Committee)
Sternberg C, Italy
Suzuki H Japan
Tannock I, Canada
Tombal B, Belgium

Endorsement (will be updated)

ESO recommended:



krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research





ADVANCED PROSTATE CANCER CONSENSUS CONFERENCE

St.Gallen / Switzerland 12 – 14 March 2015

DRAFT SCIENTIFIC PROGRAM

Thursday 12 March 2015 10am-6pm	
Session 1	Current treatment options: State of the Art <ul style="list-style-type: none"> • Role of new endocrine agents in advanced prostate cancer (APC) • Role of chemotherapy in the management of APC? • Role of immunotherapies in APC
Session 2	Bone metastases: Best management strategies <ul style="list-style-type: none"> • How to best prevent skeletal related events (SRE's) in the era of novel treatment options? • How to make best use of radium223? • Early detection and treatment of patients with malignant spinal cord compression
Session 3	Debates: The role of “vintage” hormonal manipulations <ul style="list-style-type: none"> • At progression after ADT: Is a “vintage” androgen receptor inhibitor useful? • Single agent steroids: “Dead or Alive”? • Ketoconazole: “Dead or Alive”? • Estrogens: “Dead or Alive”?
Session 4	Management of special APC clinical situations <ul style="list-style-type: none"> • Management of local complications in APC • When to use radiotherapy in APC • Small cell and anaplastic prostate cancer • Meningeal carcinomatosis and brain metastases • Management of young (<55) and old (>85) and/or frail patients • Patients with DIC and bone marrow failure
Friday 13 March 2015 8am-6.30pm	
Session 5	Management of hormone sensitive metastatic prostate cancer <ul style="list-style-type: none"> • Intermittent versus continuous ADT • Bone targeting agents in hormone sensitive metastatic prostate cancer • What's the role of docetaxel in the management of hormone sensitive metastatic prostate cancer?
Session 6	Molecular characterisation of APC – Relevance today <ul style="list-style-type: none"> • Androgen receptor and other steroid receptors: the key drivers of APC? • Mechanisms of resistance to ADT and how this informs us clinically • Current state of molecular characterisation of prostate cancer • Serum based biomarkers and CTCs • Patients with BRCA1/2 and other germline mutations
Session 7	M0 CRPC – an overview and debate <ul style="list-style-type: none"> • What imaging and when in M0 CRPC? • What treatments are recommended for M0 CRPC? • Debate: Novel survival prolonging treatments for M0 CRPC?
Session 8	Monitoring of Disease Activity: a challenging task <ul style="list-style-type: none"> • Current imaging for APC – an unsolved daily clinical problem: the radiologists view • Current imaging for APC – an unsolved daily clinical problem: the nuclear medicine view • Prostate Cancer Working Group criteria – what's the next generation? • When to change treatment for APC patients in daily practice
Session 9	How to transfer trial results into clinical practice? <ul style="list-style-type: none"> • Interpretation of trial results • Treatment decisions: Quality of life is important • Combination strategies: Is more better? • Sequencing Strategies: How to select the best sequence? • Shift from prognostication to prediction in APC: are we ready?
Session 10	Debate: Abiraterone acetate or enzalutamide as first-line treatment Debate: Chemotherapy before use of survival prolonging novel endocrine agents
Saturday 14 th of March 2015 9am-1pm	
Consensus Panel – Discussion and votes on consensus questions (open to participants)	